Skip to main content

Table 1 Baseline Characteristics by HIV and Immunological level (CD4 count) in both HIV-infected (HIV [+]) and -uninfected {HIV [-]) women

From: Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda

Parameters

HIV[-] N = 1,311

HIV[+] N = 1,228

p*

HIV[+] N = 1,228

p**

    

CD4: ≥500

CD4:350-499

CD4:200-349

CD4:<200

 
    

N = 513

N = 346

N = 271

N = 88

 

Age, years, mean ± SD

42.0 ± 8.2

40.0 ± 6.6

<0.001

39.8 ± 6.6

40.1 ± 6.7

40.8 ± 6.5

39.7 ± 6.5

0.21

Age category, years, n (%)

  

<0.001

  

0.17

 Age 30 – 34

299 (22.8)

278 (22.6)

 

127 (24.8)

81 (23.4)

51 (18.8)

16 (18.2)

 

 Age 35 – 39

279 (21.3)

359 (29.3)

 

144 (28.1)

101 (29.2)

76 (28.0)

35 (39.8)

 Age 40 – 44

237 (18.1)

295 (24.0)

 

134 (26.1)

80 (23.1)

63 (23.3)

17 (19.3)

 

 Age 45 – 49

211 (16.1)

171 (13.9)

 

58 (11.3)

49 (14.2)

49 (18.1)

13 (14.8)

 

Age at sexual initiation, years, n (%)

  

<0.001

    

0.01

 Age <14

16 (4.2)

30 (10.2)

 

11 (10.0)

5 (5.1)

7 (11.9)

7 (28.0)

 

 Age 14 – 25

338 (89.7)

258 (87.8)

 

97 (89.0)

92 (93.9)

49 (83.0)

17 (68.0)

Age at first pregnancy, years ± SD

21.1 ± 3.7

20.1 ± 3.6

<0.001

20.1 ± 3.6

20.3 ± 3.6

20.0 ± 3.7

19.4 ± 3.4

0.25

Lifetime sexual partners

  

<0.001

    

0.59

 1- 2 sexual partners

1132 (86.4)

616 (50.2)

 

260 (50.7)

179 (51.7)

126 (46.5)

43 (48.9)

 

 ≥3 sexual partners

179 (13.6)

612 (49.8)

 

253 (49.3)

167 (48.3)

145 (535)

45 (51.1)

 

Number of children delivered, n (%)

  

<0.001

    

0.01

 0 – 2

300 (23.7)

448 (39.6)

 

163 (33.9)

130 (41.3)

117 (47.8)

37 (44.6)

 

 3 – 4

500 (39.5)

464 (41.0)

 

211 (43.9)

122 (38.7)

93 (37.9)

33 (39.7)

 

 5 – 12

466 (36.8)

219 (19.4)

 

107 (22.2)

63 (20.0)

35 (14.3)

13 (15.7)

 

Rape, n (%)

  

<0.001

    

0.46

 Yes

187 (14.3)

409 (33.3)

 

164 (32.0)

124 (35.8)

85 (31.4)

33 (37.5)

 

 No

1123 (85.7)

819 (66.7)

 

349 (68.0)

222 (64.2)

186 (68.6)

55 (62.5)

 

Menopause, n (%)

  

<0.001

    

0.58

 Yes

219 (16.7)

111 (9.0)

 

50 (9.7)

26 (7.5)

28 (10.3)

7 (8.0)

 

 No

1092 (83.3)

1117 (91.0)

 

463 (90.3)

320 (92.5)

243 (89.7)

81 (92.0)

 

Polygamous relationship, n (%)

  

0.01

    

0.81

 Yes

60 (9.2)

34 (14.9)

 

15 (15.9)

8 (12.1)

8 (15.4)

3 (21.4)

 

 No

593 (90.8)

194 (85.1)

 

79 (84.1)

58 (87.9)

44 (84.6)

11 (78.6)

 

Ever used hormonal contraceptives, n (%)

  

0.002

    

< 0.001

 Yes

393 (30.1)

305 (24.8)

 

154 (30.1)

86 (24.9)

45 (16.6)

20 (22.7)

 

 No

912 (69.9)

922 (75.2)

 

358 (69.9)

260 (75.1)

226 (83.4)

68 (77.3)

 

Ever used tobacco, n (%)

  

<0.001

    

0.57

 Yes

221 (16.9)

57 (4.6)

 

25 (4.9)

11 (3.2)

13 (4.8)

5 (5.8)

 

 No

1089 (83.1)

1169 (95.4)

 

488 (95.1)

335 (96.8)

258 (95.2)

81 (94.2)

 

Antiretroviral therapy, n (%)

       

< 0.001

 Yes

N/A

948 (78.1)

 

342 (67.6)

273 (79.6)

274 (92.2)

82 (93.2)

 

 No

N/A

266 (21.9)

 

164 (32.4)

70 (20.4)

21 (7.8)

6 (6.8)

 

Malaria within 6 months, n (%)

  

<0.001

    

0.28

 Yes

185 (14.0)

95 (7.8)

 

47 (9.2)

23 (6.6)

16 (5.9)

5 (5.7)

 

 No

112 4(86.0)

1133 (92.2)

 

466 (90.8)

323 (93.4)

255 (94.1)

83 (94.3)

 

BMI, mean ± SD, kg/m ^2

21.9 ± 3.7

22.6 ± 3.8

<0.001

23.0 ± 3.8

22.7 ± 3.8

22.1 ± 3.8

22.0 ± 3.4

0.01

BMI, n (%), kg/m 2

  

<0.001

    

0.38

 12.5 – 18.5

136 (15.7)

135 (11.6)

 

44 (9.3)

41 (12.4)

38 (14.3)

11 (12.6)

 

 18.5 – 21.0

243 (28.1)

282 (24.3)

 

113 (23.8)

77 (23.3)

68 (25.6)

24 (27.6)

 

 > 21 – 39.5

486 (56.2)

744 (64.1)

 

318 (66.9)

212 (64.3)

160 (60.1)

52 (59.8)

 

HrHPV infection, n (%)*

  

<0.001

    

0.02

 Yes

107 (8.2)

390 (31.8)

 

156 (30.4)

103 (29.8)

91 (33.6)

40 (45.5)

 

 No

1,204 (91.8)

838 (68.2)

 

357 (69.6)

243 (70.3)

180 (66.4)

48 (54.5)

 
  1. SD, standard deviation and BMI, Body Mass Index. P*-value is for comparing HIV-uninfected to infected overall. P**-value is for comparing CD4 categories in HIV -infected women to different subjects’ parameters. For obtaining p-values chi-Square tests were used for categorical variables and ANOVA for continuous variables except: number of children born, where non-parametric Kruskal Wallis tests was used.